PDF(Pubmed)
Abstract：
Positron emission tomography (PET) has been widely used in paediatric oncology. 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is the most commonly used radiopharmaceutical for PET imaging. For oncological brain imaging, different amino acid PET radiopharmaceuticals have been introduced in the last years. The purpose of this document is to provide imaging specialists and clinicians guidelines for indication, acquisition, and interpretation of [18F]FDG and radiolabelled amino acid PET in paediatric patients affected by brain gliomas. There is no high level of evidence for all recommendations suggested in this paper. These recommendations represent instead the consensus opinion of experienced leaders in the field. Further studies are needed to reach evidence-based recommendations for the applications of [18F]FDG and radiolabelled amino acid PET in paediatric neuro-oncology. These recommendations are not intended to be a substitute for national and international legal or regulatory provisions and should be considered in the context of good practice in nuclear medicine. The present guidelines/standards were developed collaboratively by the EANM and SNMMI with the European Society for Paediatric Oncology (SIOPE) Brain Tumour Group and the Response Assessment in Paediatric Neuro-Oncology (RAPNO) working group. They summarize also the views of the Neuroimaging and Oncology and Theranostics Committees of the EANM and reflect recommendations for which the EANM and other societies cannot be held responsible.
摘要：
正电子发射断层扫描（PET）已广泛用于儿科肿瘤学。2-脱氧-2-[18F]氟-D-葡萄糖([18F]FDG)是用于PET成像的最常用的放射性药物。对于肿瘤脑成像，不同的氨基酸PET放射性药物已经在过去几年中被引入。本文件的目的是为影像专家和临床医生提供适应症指南，收购,并解释[18F]FDG和放射性标记的氨基酸PET在儿童患者的脑胶质瘤的影响。本文提出的所有建议都没有高水平的证据。相反，这些建议代表了该领域经验丰富的领导人的共识。对于[18F]FDG和放射性标记的氨基酸PET在小儿神经肿瘤学中的应用，需要进一步的研究以达成基于证据的建议。这些建议无意替代国家和国际法律或监管规定，应在核医学良好做法的背景下加以考虑。本指南/标准是由EANM和SNMMI与欧洲儿科肿瘤学会（SIOPE）脑肿瘤小组和儿科神经肿瘤学反应评估（RAPNO）工作组合作开发的。他们还总结了EANM的神经影像学和肿瘤学和Theranosics委员会的观点，并反映了EANM和其他社会不能对此负责的建议。
